Loading…
Discovery and evaluation of biphenyl derivatives of 2‐iminobenzimidazoles as prototype dual PTP1B inhibitors and AMPK activators with in vivo antidiabetic activity
This work describes the synthesis of series hydrobromides of N‐(4‐biphenyl)methyl–N′‐dialkylaminoethyl‐2‐iminobenzimidazoles, which, due to the presence of two privileged structural fragments (benzimidazole and biphenyl moieties), can be considered as bi‐privileged structures. Compound 7a proved to...
Saved in:
Published in: | Chemical biology & drug design 2023-04, Vol.101 (4), p.896-914 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c2888-3ab423280fa232ee8804daea45a06f804a30dcb60d87201e22b565ed83e88c593 |
container_end_page | 914 |
container_issue | 4 |
container_start_page | 896 |
container_title | Chemical biology & drug design |
container_volume | 101 |
creator | Babkov, Denis A. Zhukovskaya, Olga N. Brigadirova, Anastasia A. Prilepskaya, Diana R. Kolodina, Alexandra A. Abbas, Abbas Haider S. Morkovnik, Anatolii S. Sobhia, M. Elizabeth Ghosh, Ketan Spasov, Alexander A. |
description | This work describes the synthesis of series hydrobromides of N‐(4‐biphenyl)methyl–N′‐dialkylaminoethyl‐2‐iminobenzimidazoles, which, due to the presence of two privileged structural fragments (benzimidazole and biphenyl moieties), can be considered as bi‐privileged structures. Compound 7a proved to activate AMP‐activated kinase (AMPK) and simultaneously inhibit protein tyrosine phosphatase 1B (PTP1B) with similar potency. This renders it an interesting prototype of potential antidiabetic agents with a dual‐target mechanism of action. Using prove of concept in vivo study, we show that dual‐targeting compound 7a has a disease‐modifying effect in a rat model of type 2 diabetes mellitus via improving insulin sensitivity and lipid metabolism.
Biphenyl derivative of 2‐iminobenzimidazole acts as a high‐micromolar AMPK activator and PTP1B inhibitor with a disease‐modifying effect in a rat model of type 2 diabetes mellitus via improving insulin sensitivity and lipid metabolism. |
doi_str_mv | 10.1111/cbdd.14198 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2757055652</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2757055652</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2888-3ab423280fa232ee8804daea45a06f804a30dcb60d87201e22b565ed83e88c593</originalsourceid><addsrcrecordid>eNp9kc9u1DAQxi0Eon_gwgMgHxHSFtuJE_fY7lJAFLGHco7G8UQ7KBsvsZMqPfEIvAQvxpPgNKVHfJnx5998lv0x9kqKM5nWu9o6dyZzeW6esGNZ5uVKKKOfPvZlecROQvguRJ5rZZ6zo6zQeZGJ8pj93lCo_Yj9xKFzHEdoB4jkO-4bbumww25qucOexiSPGGZd_fn5i_bUeYvdXWoc3Pk2HUHgh95HH6cDcjdAy7c3W3nJqduRpej7cH_JxZftZw51nC1n7ZbiLjF8pNEnIJIjsBipXiCK0wv2rIE24MuHesq-Xb2_WX9cXX_98Gl9cb2qlTFmlYHNVaaMaCAVRGNE7gAh1yCKJm0gE662hXCmVEKiUlYXGp3JElrr8-yUvVl80zN-DBhitU_fg20LHfohVKrUpdBpRiX07YLWvQ-hx6Y69LSHfqqkqOZYqjmW6j6WBL9-8B3sHt0j-i-HBMgFuKUWp_9YVevLzWYx_QtVoJv3</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2757055652</pqid></control><display><type>article</type><title>Discovery and evaluation of biphenyl derivatives of 2‐iminobenzimidazoles as prototype dual PTP1B inhibitors and AMPK activators with in vivo antidiabetic activity</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Babkov, Denis A. ; Zhukovskaya, Olga N. ; Brigadirova, Anastasia A. ; Prilepskaya, Diana R. ; Kolodina, Alexandra A. ; Abbas, Abbas Haider S. ; Morkovnik, Anatolii S. ; Sobhia, M. Elizabeth ; Ghosh, Ketan ; Spasov, Alexander A.</creator><creatorcontrib>Babkov, Denis A. ; Zhukovskaya, Olga N. ; Brigadirova, Anastasia A. ; Prilepskaya, Diana R. ; Kolodina, Alexandra A. ; Abbas, Abbas Haider S. ; Morkovnik, Anatolii S. ; Sobhia, M. Elizabeth ; Ghosh, Ketan ; Spasov, Alexander A.</creatorcontrib><description>This work describes the synthesis of series hydrobromides of N‐(4‐biphenyl)methyl–N′‐dialkylaminoethyl‐2‐iminobenzimidazoles, which, due to the presence of two privileged structural fragments (benzimidazole and biphenyl moieties), can be considered as bi‐privileged structures. Compound 7a proved to activate AMP‐activated kinase (AMPK) and simultaneously inhibit protein tyrosine phosphatase 1B (PTP1B) with similar potency. This renders it an interesting prototype of potential antidiabetic agents with a dual‐target mechanism of action. Using prove of concept in vivo study, we show that dual‐targeting compound 7a has a disease‐modifying effect in a rat model of type 2 diabetes mellitus via improving insulin sensitivity and lipid metabolism.
Biphenyl derivative of 2‐iminobenzimidazole acts as a high‐micromolar AMPK activator and PTP1B inhibitor with a disease‐modifying effect in a rat model of type 2 diabetes mellitus via improving insulin sensitivity and lipid metabolism.</description><identifier>ISSN: 1747-0277</identifier><identifier>EISSN: 1747-0285</identifier><identifier>DOI: 10.1111/cbdd.14198</identifier><identifier>PMID: 36546307</identifier><language>eng</language><publisher>England</publisher><subject>AMP-Activated Protein Kinases - metabolism ; AMPK ; Animals ; Biphenyl Compounds ; diabetes mellitus ; Diabetes Mellitus, Type 2 - metabolism ; Enzyme Inhibitors - chemistry ; Hypoglycemic Agents - chemistry ; obesity ; Protein Tyrosine Phosphatase, Non-Receptor Type 1 ; PTP1B ; Rats</subject><ispartof>Chemical biology & drug design, 2023-04, Vol.101 (4), p.896-914</ispartof><rights>2022 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2888-3ab423280fa232ee8804daea45a06f804a30dcb60d87201e22b565ed83e88c593</cites><orcidid>0000-0003-3331-8990</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36546307$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Babkov, Denis A.</creatorcontrib><creatorcontrib>Zhukovskaya, Olga N.</creatorcontrib><creatorcontrib>Brigadirova, Anastasia A.</creatorcontrib><creatorcontrib>Prilepskaya, Diana R.</creatorcontrib><creatorcontrib>Kolodina, Alexandra A.</creatorcontrib><creatorcontrib>Abbas, Abbas Haider S.</creatorcontrib><creatorcontrib>Morkovnik, Anatolii S.</creatorcontrib><creatorcontrib>Sobhia, M. Elizabeth</creatorcontrib><creatorcontrib>Ghosh, Ketan</creatorcontrib><creatorcontrib>Spasov, Alexander A.</creatorcontrib><title>Discovery and evaluation of biphenyl derivatives of 2‐iminobenzimidazoles as prototype dual PTP1B inhibitors and AMPK activators with in vivo antidiabetic activity</title><title>Chemical biology & drug design</title><addtitle>Chem Biol Drug Des</addtitle><description>This work describes the synthesis of series hydrobromides of N‐(4‐biphenyl)methyl–N′‐dialkylaminoethyl‐2‐iminobenzimidazoles, which, due to the presence of two privileged structural fragments (benzimidazole and biphenyl moieties), can be considered as bi‐privileged structures. Compound 7a proved to activate AMP‐activated kinase (AMPK) and simultaneously inhibit protein tyrosine phosphatase 1B (PTP1B) with similar potency. This renders it an interesting prototype of potential antidiabetic agents with a dual‐target mechanism of action. Using prove of concept in vivo study, we show that dual‐targeting compound 7a has a disease‐modifying effect in a rat model of type 2 diabetes mellitus via improving insulin sensitivity and lipid metabolism.
Biphenyl derivative of 2‐iminobenzimidazole acts as a high‐micromolar AMPK activator and PTP1B inhibitor with a disease‐modifying effect in a rat model of type 2 diabetes mellitus via improving insulin sensitivity and lipid metabolism.</description><subject>AMP-Activated Protein Kinases - metabolism</subject><subject>AMPK</subject><subject>Animals</subject><subject>Biphenyl Compounds</subject><subject>diabetes mellitus</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Enzyme Inhibitors - chemistry</subject><subject>Hypoglycemic Agents - chemistry</subject><subject>obesity</subject><subject>Protein Tyrosine Phosphatase, Non-Receptor Type 1</subject><subject>PTP1B</subject><subject>Rats</subject><issn>1747-0277</issn><issn>1747-0285</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kc9u1DAQxi0Eon_gwgMgHxHSFtuJE_fY7lJAFLGHco7G8UQ7KBsvsZMqPfEIvAQvxpPgNKVHfJnx5998lv0x9kqKM5nWu9o6dyZzeW6esGNZ5uVKKKOfPvZlecROQvguRJ5rZZ6zo6zQeZGJ8pj93lCo_Yj9xKFzHEdoB4jkO-4bbumww25qucOexiSPGGZd_fn5i_bUeYvdXWoc3Pk2HUHgh95HH6cDcjdAy7c3W3nJqduRpej7cH_JxZftZw51nC1n7ZbiLjF8pNEnIJIjsBipXiCK0wv2rIE24MuHesq-Xb2_WX9cXX_98Gl9cb2qlTFmlYHNVaaMaCAVRGNE7gAh1yCKJm0gE662hXCmVEKiUlYXGp3JElrr8-yUvVl80zN-DBhitU_fg20LHfohVKrUpdBpRiX07YLWvQ-hx6Y69LSHfqqkqOZYqjmW6j6WBL9-8B3sHt0j-i-HBMgFuKUWp_9YVevLzWYx_QtVoJv3</recordid><startdate>202304</startdate><enddate>202304</enddate><creator>Babkov, Denis A.</creator><creator>Zhukovskaya, Olga N.</creator><creator>Brigadirova, Anastasia A.</creator><creator>Prilepskaya, Diana R.</creator><creator>Kolodina, Alexandra A.</creator><creator>Abbas, Abbas Haider S.</creator><creator>Morkovnik, Anatolii S.</creator><creator>Sobhia, M. Elizabeth</creator><creator>Ghosh, Ketan</creator><creator>Spasov, Alexander A.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3331-8990</orcidid></search><sort><creationdate>202304</creationdate><title>Discovery and evaluation of biphenyl derivatives of 2‐iminobenzimidazoles as prototype dual PTP1B inhibitors and AMPK activators with in vivo antidiabetic activity</title><author>Babkov, Denis A. ; Zhukovskaya, Olga N. ; Brigadirova, Anastasia A. ; Prilepskaya, Diana R. ; Kolodina, Alexandra A. ; Abbas, Abbas Haider S. ; Morkovnik, Anatolii S. ; Sobhia, M. Elizabeth ; Ghosh, Ketan ; Spasov, Alexander A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2888-3ab423280fa232ee8804daea45a06f804a30dcb60d87201e22b565ed83e88c593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>AMP-Activated Protein Kinases - metabolism</topic><topic>AMPK</topic><topic>Animals</topic><topic>Biphenyl Compounds</topic><topic>diabetes mellitus</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Enzyme Inhibitors - chemistry</topic><topic>Hypoglycemic Agents - chemistry</topic><topic>obesity</topic><topic>Protein Tyrosine Phosphatase, Non-Receptor Type 1</topic><topic>PTP1B</topic><topic>Rats</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Babkov, Denis A.</creatorcontrib><creatorcontrib>Zhukovskaya, Olga N.</creatorcontrib><creatorcontrib>Brigadirova, Anastasia A.</creatorcontrib><creatorcontrib>Prilepskaya, Diana R.</creatorcontrib><creatorcontrib>Kolodina, Alexandra A.</creatorcontrib><creatorcontrib>Abbas, Abbas Haider S.</creatorcontrib><creatorcontrib>Morkovnik, Anatolii S.</creatorcontrib><creatorcontrib>Sobhia, M. Elizabeth</creatorcontrib><creatorcontrib>Ghosh, Ketan</creatorcontrib><creatorcontrib>Spasov, Alexander A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Chemical biology & drug design</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Babkov, Denis A.</au><au>Zhukovskaya, Olga N.</au><au>Brigadirova, Anastasia A.</au><au>Prilepskaya, Diana R.</au><au>Kolodina, Alexandra A.</au><au>Abbas, Abbas Haider S.</au><au>Morkovnik, Anatolii S.</au><au>Sobhia, M. Elizabeth</au><au>Ghosh, Ketan</au><au>Spasov, Alexander A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discovery and evaluation of biphenyl derivatives of 2‐iminobenzimidazoles as prototype dual PTP1B inhibitors and AMPK activators with in vivo antidiabetic activity</atitle><jtitle>Chemical biology & drug design</jtitle><addtitle>Chem Biol Drug Des</addtitle><date>2023-04</date><risdate>2023</risdate><volume>101</volume><issue>4</issue><spage>896</spage><epage>914</epage><pages>896-914</pages><issn>1747-0277</issn><eissn>1747-0285</eissn><abstract>This work describes the synthesis of series hydrobromides of N‐(4‐biphenyl)methyl–N′‐dialkylaminoethyl‐2‐iminobenzimidazoles, which, due to the presence of two privileged structural fragments (benzimidazole and biphenyl moieties), can be considered as bi‐privileged structures. Compound 7a proved to activate AMP‐activated kinase (AMPK) and simultaneously inhibit protein tyrosine phosphatase 1B (PTP1B) with similar potency. This renders it an interesting prototype of potential antidiabetic agents with a dual‐target mechanism of action. Using prove of concept in vivo study, we show that dual‐targeting compound 7a has a disease‐modifying effect in a rat model of type 2 diabetes mellitus via improving insulin sensitivity and lipid metabolism.
Biphenyl derivative of 2‐iminobenzimidazole acts as a high‐micromolar AMPK activator and PTP1B inhibitor with a disease‐modifying effect in a rat model of type 2 diabetes mellitus via improving insulin sensitivity and lipid metabolism.</abstract><cop>England</cop><pmid>36546307</pmid><doi>10.1111/cbdd.14198</doi><tpages>19</tpages><orcidid>https://orcid.org/0000-0003-3331-8990</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1747-0277 |
ispartof | Chemical biology & drug design, 2023-04, Vol.101 (4), p.896-914 |
issn | 1747-0277 1747-0285 |
language | eng |
recordid | cdi_proquest_miscellaneous_2757055652 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | AMP-Activated Protein Kinases - metabolism AMPK Animals Biphenyl Compounds diabetes mellitus Diabetes Mellitus, Type 2 - metabolism Enzyme Inhibitors - chemistry Hypoglycemic Agents - chemistry obesity Protein Tyrosine Phosphatase, Non-Receptor Type 1 PTP1B Rats |
title | Discovery and evaluation of biphenyl derivatives of 2‐iminobenzimidazoles as prototype dual PTP1B inhibitors and AMPK activators with in vivo antidiabetic activity |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T04%3A37%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discovery%20and%20evaluation%20of%20biphenyl%20derivatives%20of%202%E2%80%90iminobenzimidazoles%20as%20prototype%20dual%20PTP1B%20inhibitors%20and%20AMPK%20activators%20with%20in%20vivo%20antidiabetic%20activity&rft.jtitle=Chemical%20biology%20&%20drug%20design&rft.au=Babkov,%20Denis%20A.&rft.date=2023-04&rft.volume=101&rft.issue=4&rft.spage=896&rft.epage=914&rft.pages=896-914&rft.issn=1747-0277&rft.eissn=1747-0285&rft_id=info:doi/10.1111/cbdd.14198&rft_dat=%3Cproquest_cross%3E2757055652%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2888-3ab423280fa232ee8804daea45a06f804a30dcb60d87201e22b565ed83e88c593%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2757055652&rft_id=info:pmid/36546307&rfr_iscdi=true |